Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2019 Jan 3;174(3):615–625. doi: 10.1007/s10549-018-05104-9

Fig. 2: Combination of palbocilclib and MLN0128 synergistically inhibited proliferation of MB231 and MB453.

Fig. 2:

(A and C) MB231, MB453, MB468, and CAL148 cells were treated with palbociclib and/or MLN0128 for 120 h. The X axis shows palbociclib concentration. (B) Combination index (CI) was calculated in MB231 and in MB453. CI > 1 means antagonistic effect, = 1 means additive effect, and < 1 means synergistic effect. (D) MB231 and MB453 cells were treated with palbociclib and/or everolimus at the indicated concentrations. Results of MTT assay are expressed as the ratio of control, and are mean ± SD at each treatment concentration, from triplicate measurements for each treatment.